Literature DB >> 10932079

Negative regulation of FcepsilonRI signaling by FcgammaRII costimulation in human blood basophils.

C L Kepley1, J C Cambier, P A Morel, D Lujan, E Ortega, B S Wilson, J M Oliver.   

Abstract

BACKGROUND: Signaling through the antigen receptors of human B and T cells and the high-affinity IgE receptor FcepsilonRI of rodent mast cells is decreased by cross-linking these receptors to the low-affinity IgG receptor FcgammaRII. The inhibition is thought to involve the tyrosine phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in the FcgammaRIIB cytoplasmic tail, creating binding sites for SH2-containing protein (Src homology domain containing protein tyrosine phosphatase 1 and 2 [SHP-1, SHP-2]) and/or lipid (SH2 domain-containing polyphosphatidyl-inositol 5-phosphatase) phosphatases that oppose activating signals from the costimulated antigen receptors.
OBJECTIVE: In human basophils and mast cells FcepsilonRI signaling generates mediators and cytokines responsible for allergic inflammation. We proposed to determine whether FcepsilonRI signaling is inhibited by FcgammaRII costimulation in human basophils and to explore the underlying mechanism as an approach to improving the treatment of allergic inflammation.
METHODS: FcgammaR expression on human basophils was examined using flow cytometry and RT-PCR analysis. FcgammaRII/FcepsilonRI costimulation was typically accomplished by priming cells with anti-dinitrophenol (DNP) IgE and anti-DNP IgG and stimulating with DNP-BSA. Phosphatases were identified by Western blotting, and their partitioning between membrane and cytosol was determined by cell fractionation. Biotinylated synthetic peptides and phosphopeptides corresponding to the FcgammaRIIB ITIM sequence were used for adsorption assays.
RESULTS: We report that peripheral blood basophils express FcgammaRII (in both the ITIM-containing FcgammaRIIB and the immunoreceptor tyrosine-based activation motif-containing FcgammaRIIA forms) and that costimulating FcgammaRII and FcepsilonRI inhibits basophil FcepsilonRI-mediated histamine release, IL-4 production, and Ca(2+) mobilization. The inhibition of basophil FcepsilonRI signaling by FcgammaRII/FcepsilonRI costimulation is linked to a significant decrease in Syk tyrosine phosphorylation. Human basophils express all 3 SH2-containing phosphatases.
CONCLUSIONS: Evidence that FcgammaRII/FcepsilonRI costimulation induces SHP-1 translocation from the cytosolic to membrane fractions of basophils and that biotinylated synthetic peptides corresponding to the phosphorylated FcgammaRIIB ITIM sequence specifically recruit SHP-1 from basophil lysates particularly implicates this protein phosphatase in the negative regulation of FcepsilonRI signaling by costimulated FcgammaRII.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10932079     DOI: 10.1067/mai.2000.107931

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  34 in total

1.  Structural and immunologic cross-reactivity among filarial and mite tropomyosin: implications for the hygiene hypothesis.

Authors:  Helton C Santiago; Sasisekhar Bennuru; Alexis Boyd; Mark Eberhard; Thomas B Nutman
Journal:  J Allergy Clin Immunol       Date:  2010-12-24       Impact factor: 10.793

2.  Prevention and treatment of allergic inflammation by an Fcγ-Der f2 fusion protein in a murine model of dust mite-induced asthma.

Authors:  Li-hui Lin; Ping Zheng; John W M Yuen; Juan Wang; Juan Zhou; Cun-quan Kong; Xia Peng; Jia Li; Li Li
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

3.  Autoantibodies to IgE and FcεRI and the natural variability of spleen tyrosine kinase expression in basophils.

Authors:  Donald MacGlashan
Journal:  J Allergy Clin Immunol       Date:  2018-06-01       Impact factor: 10.793

Review 4.  New approaches to allergen immunotherapy.

Authors:  Christopher L Kepley
Journal:  Curr Allergy Asthma Rep       Date:  2006-09       Impact factor: 4.806

5.  Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children.

Authors:  A Thyagarajan; S M Jones; A Calatroni; L Pons; M Kulis; C S Woo; M Kamalakannan; B P Vickery; A M Scurlock; A Wesley Burks; W G Shreffler
Journal:  Clin Exp Allergy       Date:  2012-08       Impact factor: 5.018

Review 6.  Applications and mechanisms of immunotherapy in allergic rhinitis and asthma.

Authors:  Jasper H Kappen; Stephen R Durham; Hans In 't Veen; Mohamed H Shamji
Journal:  Ther Adv Respir Dis       Date:  2016-09-27       Impact factor: 4.031

7.  IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB.

Authors:  Carol T Cady; Maree S Powell; Ronald J Harbeck; Patricia C Giclas; James R Murphy; Rohit K Katial; Richard W Weber; P Mark Hogarth; Syd Johnson; Ezio Bonvini; Scott Koenig; John C Cambier
Journal:  Immunol Lett       Date:  2009-12-30       Impact factor: 3.685

Review 8.  Human Helminths and Allergic Disease: The Hygiene Hypothesis and Beyond.

Authors:  Helton C Santiago; Thomas B Nutman
Journal:  Am J Trop Med Hyg       Date:  2016-08-29       Impact factor: 2.345

9.  Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.

Authors:  Janet Jackman; Yongmei Chen; Arthur Huang; Barbara Moffat; Justin M Scheer; Steven R Leong; Wyne P Lee; Juan Zhang; Navneet Sharma; Yanmei Lu; Suhasini Iyer; Robert L Shields; Nancy Chiang; Michele C Bauer; Diana Wadley; Merone Roose-Girma; Richard Vandlen; Daniel G Yansura; Yan Wu; Lawren C Wu
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

10.  FcgammaRIIb inhibits allergic lung inflammation in a murine model of allergic asthma.

Authors:  Nilesh Dharajiya; Swapnil V Vaidya; Hiroki Murai; Victor Cardenas; Alexander Kurosky; Istvan Boldogh; Sanjiv A Sur
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.